2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations

EP.12D.05 MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations

Back to course

Pdf Summary

The document presents an analysis comparing the effectiveness and safety of the drug Capmatinib (CAP) with other MET inhibitors—Savolitinib (SAV), Glumetinib (GLU), and Tepotinib (TEP)—for treating advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutations. This subtype of lung cancer is significant due to its high incidence and mortality rates.<br /><br />This study utilizes a Matching-Adjusted Indirect Comparison (MAIC) to estimate the overall survival (OS) and treatment-related adverse events (TRAE) of patients undergoing treatment with CAP versus the other MET inhibitors. Due to the absence of direct comparative trials, the MAIC technique provides a way to balance patient baseline characteristics across different studies allowing for a comparative analysis.<br /><br />The findings indicate that CAP shows a trend towards improved overall survival compared to SAV and TEP, although these benefits were not statistically significant. However, CAP patients experienced fewer treatment-related adverse events compared to those taking SAV and GLU, with significance in the general and Asian populations. <br /><br />The results suggest that capmatinib might be a more tolerable option with better survival trends for certain patient populations, although further studies with larger sample sizes or direct head-to-head comparisons are recommended to confirm these findings.<br /><br />Despite these promising results, the analysis acknowledges some limitations, including the relatively small sample sizes and potential residual confounding factors not addressed by MAIC methodology. The study emphasizes the need for future research that includes additional and newly approved MET inhibitors for a more comprehensive understanding of treatment options.<br /><br />Overall, while CAP shows promise as an effective treatment for patients with these specific genetic mutations, robust comparative studies remain vital to guide clinical decision-making in this complex field.

Asset Subtitle

Yu Yao

Meta Tag

Speaker Yu Yao

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Capmatinib

MET inhibitors

non-small cell lung cancer

MET exon 14 skipping mutations

Matching-Adjusted Indirect Comparison

overall survival

treatment-related adverse events

Savolitinib

Glumetinib

Tepotinib